IO Biotech Company
IO Biotech is a clinical-stage biotech company developing disruptive immune therapies for the treatment of cancer.
Last Funding Type:
Series C
Last Funding Date:
2021-10-07
Funding Status:
IPO
Headquarters:
Copenhagen, Hovedstaden, Denmark
Industry:
Peptides and Proteins
Estimated Revenue:
$1M to $10M
Total Funding:
175012360
Investors Number:
16
Employee Number:
11-50
Founded Date:
2014-12-23